Summary

Eligibility
for people ages 18 years and up (full criteria)
Location
at La Jolla, California and other locations
Dates
study started
completion around

Description

Summary

This phase I trial studies the side effects and best dose of ropidoxuridine when given together with whole brain radiation therapy in treating patients with cancer that has spread to the brain (brain metastases). Ropidoxuridine may help whole brain radiation therapy work better by making cancer cells more sensitive to the radiation therapy.

Official Title

Phase 1 and Pharmacology Study of Oral 5-Iodo-2-Pyrimidinone-2-Deoxyribose (IPdR) as a Prodrug for IUdR-Mediated Tumor Radiosensitization in Brain Metastases

Details

Keywords

Hematopoietic and Lymphoid Cell Neoplasm, Malignant Solid Neoplasm, Metastatic Malignant Neoplasm in the Brain, Neoplasms, Brain Neoplasms, Ropidoxuridine, Laboratory Biomarker Analysis, Pharmacological Study, Quality-of-Life Assessment, Whole-Brain Radiotherapy

Eligibility

Locations

  • UC San Diego Moores Cancer Center
    La Jolla California 92093 United States
  • University of California Davis Comprehensive Cancer Center
    Sacramento California 95817 United States

Details

Status
in progress, not accepting new patients
Start Date
Completion Date
(estimated)
Sponsor
National Cancer Institute (NCI)
ID
NCT02993146
Phase
Phase 1 research study
Study Type
Interventional
Participants
About 11 people participating
Last Updated